ArticleVirchows Archiv : an international journal of pathology2026
Real world clinical characteristics of Claudin 18.2 expression in patients with pancreatic adenocarcinoma.
Article in Virchows Archiv : an international journal of pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Intra- and intertumoral discordance of Claudin-18.2: a systematic review and meta-analysis.ESMO gastrointestinal oncology · 2026Review
- Bispecific antibodies in gastrointestinal cancers: current applications and future perspectives.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Claudin 18.2 (CLDN18.2) is a protein overexpressed in primary cancers of a few sites, including pancreatic ductal adenocarcinoma (PDAC). Recent clinical trials demonstrated prolonged progression-free survival and overall survival with an anti-CLDN18.2 agent plus chemotherapy in gastric or gastroesophageal adenocarcinoma patients. Recognizing the potential for efficacy in PDAC, which is also a morphologically and immunophenotypically similar malignancy, we investigated the prevalence and clinicopathologic features of CLDN18.2 immunohistochemical expression in a large cohort of PDAC cases and paired metastases. Two-hundred eighty (83.1%) of the included 337 cases had some degree of expression of CLDN18.2 (any staining intensity), and 90 (26.7%, 95% confidence interval [CI]: 22.3%-31.7%) would be classified as CLDN18.2-positive using the previously defined criteria used in clinical trials for gastroesophageal adenocarcinoma (moderate or strong membranous CLDN18.2 staining in ≥ 75% of tumor cells). Most cases (78 of 102, 76.5%) showed agreement for CLDN18.2 status based on the primary tumor compared to metastatic tissue. CLDN18.2-positive cases had lower tumor grade (p = 0.009), lower pre-operative carcinoembryonic antigen (p = 0.04) and carbohydrate antigen 19 - 9 levels (p = 0.002), and were less likely to have received neoadjuvant chemoradiation (p < 0.001) than CLDN18.2-negative cases. Outcome data showed CLDN18.2 positivity had a slightly protective effect among patients with neoadjuvant therapy (HR = 0.66, 95% CI: 0.43-0.99, p = 0.04). Our findings suggest value in the development of biomarker and morphology-driven clinical trials of anti-CLDN18.2 agents in PDAC, representing the potential for a novel therapeutic avenue for patients.
Indexed as
Identifiers
42080920What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.